|Price and Volume|
|52 Week High||9.89|
|52 Week Low||4.90|
|Avg. Daily Vol. (Mil)||4.01|
|Beta (3 year)||1.60|
|Share Related Items|
|Mkt Cap (Mil)||1,496.18|
|Shares Out (Mil)||188.56|
|LT Debt/ Equity||9.71|
|Total Debt / Equity||9.89|
|Per Share Data|
|ARIAD Pharmaceuticals Inc is an oncology company. The Company is engaged in transforming the lives of cancer patients with breakthrough medicines. It commercializes & develops products and product candidates including Iclusig, Brigatinib, and AP32788.|
|26 Landsdowne Street
Cambridge, MA 02139-4234
|Industry : Drugs|
|Sector: Health Care|
|CEO: Dr. Harvey J. Berger,M.D|
|Current Month (Mil)||45.35|
|Previous Month (Mil)||44.63|
|Short Interest Ratio (Days)||14.90|
|Return on Equity||n.a.|
|Return on Assets||-28.50|
|Return on Investments||-40.60|
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.